Document is current
Any future updates will be listed below
-
Authors
Maus, Mate https://orcid.org/0000-0002-2128-2479
López-Polo, Vanessa https://orcid.org/0000-0001-6165-2510
Mateo, Lidia https://orcid.org/0000-0002-9076-4025
Lafarga, Miguel
Aguilera, Mònica https://orcid.org/0000-0003-0763-7947
De Lama, Eugenia
Meyer, Kathleen
Sola, Anna https://orcid.org/0000-0003-2379-9313
Lopez-Martinez, Cecilia https://orcid.org/0000-0001-7269-4126
López-Alonso, Ines
Guasch-Piqueras, Marc https://orcid.org/0000-0003-2392-2860
Hernandez-Gonzalez, Fernanda https://orcid.org/0000-0001-5113-4285
Chaib, Selim https://orcid.org/0000-0003-0497-2002
Rovira, Miguel https://orcid.org/0000-0002-1391-8465
Sanchez, Mayka https://orcid.org/0000-0002-6499-5989
Faner, Rosa
Agusti, Alvar https://orcid.org/0000-0003-3271-3788
Diéguez-Hurtado, Rodrigo
Ortega, Sagrario
Manonelles, Anna https://orcid.org/0000-0003-2456-388X
Engelhardt, Stefan https://orcid.org/0000-0001-5378-8661
Monteiro, Freddy https://orcid.org/0000-0002-9080-6715
Stephan-Otto Attolini, Camille https://orcid.org/0000-0001-8045-320X
Prats, Neus
Albaiceta, Guillermo https://orcid.org/0000-0002-9276-3253
Cruzado, Josep M. https://orcid.org/0000-0003-1388-8558
Serrano, Manuel https://orcid.org/0000-0001-7177-9312
- License Information
-
More Information
Article History
Received: 28 July 2022
Accepted: 11 October 2023
First Online: 14 December 2023
Competing interests
: M. Serrano is a shareholder of Senolytic Therapeutics, Life Biosciences, Rejuveron Senescence Therapeutics and Altos Labs and is an advisor to Rejuveron Senescence Therapeutics and Altos Labs. M. Serrano has been a consultant, until the end of 2022, for Rejuveron Senescence Therapeutics and Altos Labs. The funders had no role in the study design, data collection and analysis, decision to publish or manuscript preparation. The remaining authors declare no competing interests.
